Results 11 to 20 of about 257,416 (262)

DKK1 as a robust predictor for adjuvant platinum chemotherapy benefit in resectable pStage II-III gastric cancer

Translational Oncology, 2023
Background: Adjuvant chemotherapy (ACT) with 5-FU alone or 5-FU plus platinum after curative surgery improves the prognosis of pStage II-III gastric cancer (GC). However, only a subset of patients benefits from adjuvant platinum.
Zhiyuan Fan, Beiqin Yu, Tao Pan, Fangyuan Li, Jianfang Li, Junyi Hou, Wentao Liu, Liping Su, Zhenggang Zhu, Chao Yan, Bingya Liu   +10 more
doaj   +1 more source

A quick and reliable image-based AI algorithm for evaluating cellular senescence of gastric organoids

Cancer Biology & Medicine, 2023
Objective: Organoids are a powerful tool with broad application prospects in biomedicine. Notably, they provide alternatives to animal models for testing potential drugs before clinical trials. However, the number of passages for which organoids maintain
Ruixin Yang, Yutong Du, Wingyan Kwan, Ranlin Yan, Qimeng Shi, Lu Zang, Zhenggang Zhu, Jianming Zhang, Chen Li, Yingyan Yu   +9 more
doaj   +1 more source

Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer

Frontiers in Pharmacology, 2018
Exploring ERBB2-related pathways will help us finding sensitive molecules and potential combined therapeutic targets of ERBB2-targeted therapy for ERBB2+ gastric cancer (GC). In this study, we performed a cross-databases study focused on ERBB2+ GC.
Zhen Xiang, Xia Huang, Jiexuan Wang, Jun Zhang, Jun Ji, Ranlin Yan, Zhenggang Zhu, Wei Cai, Yingyan Yu   +8 more
doaj   +1 more source

Feasibility of Preserving No. 5 and No. 6 Lymph Nodes in Gastrectomy of Proximal Gastric Adenocarcinoma: A Retrospective Analysis of 395 Patients

Frontiers in Oncology, 2022
ObjectiveThe extent of regional lymphadenectomy for proximal gastric cancer (PGC) has remained a controversy and a matter of considerable debate for a long time.
Xiao Yang, Xiao Yang, Yanan Zheng, Runhua Feng, Zhenggang Zhu, Min Yan, Chen Li   +6 more
doaj   +1 more source

A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis

Journal of Experimental & Clinical Cancer Research, 2019
Background IDO1 (Indoleamine 2,3-dioxygenase 1) inhibits host anti-tumor immune response by exhausting tryptophan in tumor microenvironment, but the pathogenic mechanisms of IDO1 in gastric cancer (GC) cells need to be further explored.
Zhen Xiang, Jun Li, Shuzheng Song, Jiexuan Wang, Wei Cai, Wenjun Hu, Jun Ji, Zhenggang Zhu, Lu Zang, Ranlin Yan, Yingyan Yu   +10 more
doaj   +1 more source

Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data

EBioMedicine, 2021
Background: Due to the molecular mechanism complexity and heterogeneity of gastric cancer (GC), mechanistically interpretable biomarkers were required for predicting prognosis and discovering therapeutic targets for GC patients. Methods: Based on a total
Fangyuan Li, Jianfang Li, Junxian Yu, Tao Pan, Beiqin Yu, Qingqing Sang, Wentao Dai, Junyi Hou, Chao Yan, Mingde Zang, Zhenggang Zhu, Liping Su, Yuan-Yuan Li, Bingya Liu   +13 more
doaj   +1 more source

BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis

Advanced Science, 2023
Erlotinib, an EGFR tyrosine kinase inhibitor, is used for treating patients with cancer exhibiting EGFR overexpression or mutation. However, the response rate of erlotinib is low among patients with gastric cancer (GC).
Fangyuan Li, Junxian Yu, Tao Pan, Haoran Feng, Jianfang Li, Beiqin Yu, Zhiyuan Fan, Qingqing Sang, Mengdi Chen, Mingde Zang, Junyi Hou, Xiongyan Wu, Yingyan Yu, Yuan‐Yuan Li, Chao Yan, Zhenggang Zhu, Liping Su, Bingya Liu   +17 more
doaj   +1 more source

Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research

World Journal of Surgical Oncology, 2020
Background The high incidence of gastric cancer (GC) and paradoxical high prevalence of advanced stage GC, amounting to around 2/3 at time of diagnosis, have urged doctors and researchers around the world not only to ameliorate the detection rate of GC ...
Maneesh Kumarsing Beeharry, Tian Qi Zhang, Wen Tao Liu, Zhu Zheng Gang   +3 more
doaj   +1 more source

Is adjuvant chemotherapy necessary for early gastric cancer?

Cancer Biology & Medicine, 2022
Objective: To quantify the potential benefit of adjuvant chemotherapy (ACT) with respect to survival, and to identify factors for predicting prognoses in early gastric cancer patients.
Yu Mei, Tienan Feng, Min Yan, Zhenggang Zhu, Zhenglun Zhu   +4 more
doaj   +1 more source

Chinese interpretation of Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) and Ruijin clinical practice [PDF]

Waike lilun yu shijian, 2023
“Japanese Gastric Cancer Treatment Guidelines” have been important guidelines for the treatment of gastric cancer in Japan and worldwide. The English version “Japanese Gastric Cancer Treatment Guidelines 2021 (6th Edition)” published in January 2023 ...
YAN Chao, LU Sheng, YAN Min, ZHU Zhenggang
doaj   +1 more source